Clinical Trials Directory

Trials / Completed

CompletedNCT04792814

Cell Salvage and Retrograde Autologous Priming

Intraoperative Cell Salvage and Retrograde Autologous Priming in Patients Undergoing Isolated Coronary Bypass Grafting and Conventional Aortic Valve Replacement.

Status
Completed
Phase
Study type
Observational
Enrollment
200 (actual)
Sponsor
University Hospital Schleswig-Holstein · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

In recent years Patient Blood Management (PBM) has developed into a multifactorial and interdisciplinary concept that focuses on individualized and optimized hemotherapy. Of course, this also applies to the cardiac surgery area (1). In this context, the quality of the intraoperative PBM can be represented by patients scheduled for isolated coronary artery bypass grafting (CABG) and isolated aortic valve replacement (AVR). In a prospective, observational "before-and-after" protocol, the investigators analysed the impact of the combined use of retrograde autologous priming (RAP) and cell salvage on intraoperative usage of red blood cell concentrates (RBC) (2).

Detailed description

200 patients (CABG or AVR) will be monitored using local standard of care in these patients without cell salvage and RAP (control group, CG), followed by 200 patients with cell salvage and RAP (study group, SG). Both groups are defined by elective surgery and hemodynamically stable patients prior to the onset of the cardiopulmonary bypass (CPB). Based on our own data and current data from the literature, the investigators assume that the use of MAT in combination with RAP leads to at least an intraoperative reduction of the erythrocyte consumption of 15%. Consequently, the investigators calculated a case number of approximately 200 patients per group. The study is set up with a control group under previous standard therapy. The data is recorded and analyzed descriptively. Qualitative comparisons will be made in the discussion of previously published data.

Conditions

Timeline

Start date
2018-06-01
Primary completion
2019-10-31
Completion
2019-10-31
First posted
2021-03-11
Last updated
2021-03-11

Locations

2 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT04792814. Inclusion in this directory is not an endorsement.